| Panel Type | Target | Panel Name | Description |
|---|---|---|---|
| Comprehensive Screening Panel | Unspecific | ICECP 170 panel | A comprehensive cancer cell panel model designed to evaluate drug efficacy across 170 diverse cancer cell lines, representing a wide range of tumor types and genetic backgrounds. |
| ICECP 30 panel | A focused cancer cell panel model consisting of 30 well-characterized cell lines | ||
| Cell panel based CDX models | In vivo systems where human cancer cell lines are implanted into immunocompromised mice, enabling the study of tumor growth and therapeutic responses in a living organism. | ||
| Target-Specific Panel | RAS (2D and 3D) | Pan KRAS 20 cell panel | - Total Panels: 20+ RAS-related panels (constantly updated). - Composition: 20 or 40 cell lines, fixed, covering 5-15 cancer types. - Mutations: Focus on KRAS G12C, G12V, G12D, and NRAS mutations. - Assay Formats: 2D/3D Cell titer-Glo assays available. - Assay Duration: 5-7 days. - Plate Formats: 384-well or 96-well. - Turnaround Time: 2-3 weeks. - Special Panels: Includes RAS-resistant and BAF3 cell line options. |
| Pan KRAS 40 cell panel | |||
| KRAS G12D 20 cell panel | |||
| KRAS G12D 40 cell panel | |||
| KRAS G12C 20 cell panel | |||
| KRAS G12C 40 cell panel | |||
| KRAS G12V 20 cell panel | |||
| KRAS G12V 40 cell panel | |||
| Pan NRAS 20 cell panel | |||
| Pan NRAS 40 cell panel | |||
| Customized RAS cell panel | Customized cell panel with flexible selection for evaluating inhibitor efficacy against HRAS, KRAS, and NRAS mutations, and validating drug selectivity. Competitively priced. | ||
| DNA Damage Response | DDR 30 2D cell panel | - 30 or 65 cell lines for detecting DDR-related targets. - Validating monotherapy and combination therapy using engineered and drug-resistant cells. - Mutation Information: DDR genes such as BRCA, TP53. - Assay Duration: 3-7 days or 7-10 days. - Plate Format: 384-well or 96-well plates. - TAT: 3-4 weeks. | |
| DDR 65 2D cell panel | |||
| DDR Customized 2D cell panel | Offering flexible cell line selection. | ||
| PARP1/2 | PARP 30 2D cell panel | - 30 or 50 cell lines targeting PARP1/2. - Validating monotherapy and combination therapy efficacy using engineered and drug-resistant cells. - Mutation Information: PARP1/2-related genes (e.g., BRCA status). - Assay Duration: ~7 days. - TAT: 2-3 weeks. | |
| PARP 50 2D cell panel | |||
| BRCA mutated 2D cell panel | Customized PARP1/2 cell panel. | ||
| WRN | WRN 30 2D cell panel | - 30 or 50 cell lines targeting WRN. - Up to 10% cell line changes allowed with no price increase. - Cell Types: Tumor cells with MSI, MSS, and MSI-high status, including WRN resistant cell lines. - Assay Duration: 5-7 days. - TAT: 4-5 weeks. | |
| WRN 50 2D cell panel | |||
| WRN Customized 2D cell panel | Allows for flexible selection from 96 tumor cells with MSI, MSS, and MSI-high statuses, offering flexible cell line selection and DDR gene mutation information. | ||
| Cancer-Specific Panel | Custom Breast Cancer Cell Panel | Allows for selection from 50+ cell lines, including subtypes such as luminal A, luminal B, HER2-positive, and TNBC. | |
| Custom Colorectal Cancer Cell Panel | Allows for selection from 40+ cell lines | ||
| Novel Molecule Panel | HER2 ADC panel | - Total Composition: 65 cell lines, consisting of 53 tumor cell lines plus 12 BAF3 cell lines. - Cancer Types: Includes 10 different cancer types. - HER2 Status: Features both HER2-positive and HER2-negative cell lines. - In Vitro Bystander Effect Panel: Available for evaluating different targets and applications. - In Vivo Bystander Effect Evaluation: Conducted in mice using a mixture of Ag+ cancer cells and Ag--Luc cells, monitored with an in vivo imaging system. | |
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
